|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STK26 |
Gene summary for STK26 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STK26 | Gene ID | 51765 |
| Gene name | serine/threonine kinase 26 | |
| Gene Alias | MASK | |
| Cytomap | Xq26.2 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | Q9P289 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51765 | STK26 | LZE4T | Human | Esophagus | ESCC | 7.99e-04 | 1.10e-01 | 0.0811 |
| 51765 | STK26 | LZE7T | Human | Esophagus | ESCC | 1.26e-08 | 5.19e-01 | 0.0667 |
| 51765 | STK26 | LZE24T | Human | Esophagus | ESCC | 5.72e-17 | 4.34e-01 | 0.0596 |
| 51765 | STK26 | LZE21T | Human | Esophagus | ESCC | 5.90e-04 | 1.81e-01 | 0.0655 |
| 51765 | STK26 | LZE6T | Human | Esophagus | ESCC | 1.33e-14 | 2.53e-01 | 0.0845 |
| 51765 | STK26 | P2T-E | Human | Esophagus | ESCC | 8.46e-17 | 3.59e-01 | 0.1177 |
| 51765 | STK26 | P4T-E | Human | Esophagus | ESCC | 7.48e-17 | 3.53e-01 | 0.1323 |
| 51765 | STK26 | P5T-E | Human | Esophagus | ESCC | 1.43e-12 | 1.40e-01 | 0.1327 |
| 51765 | STK26 | P8T-E | Human | Esophagus | ESCC | 2.41e-14 | 1.28e-01 | 0.0889 |
| 51765 | STK26 | P9T-E | Human | Esophagus | ESCC | 1.20e-09 | 2.23e-01 | 0.1131 |
| 51765 | STK26 | P10T-E | Human | Esophagus | ESCC | 8.24e-18 | 1.91e-01 | 0.116 |
| 51765 | STK26 | P12T-E | Human | Esophagus | ESCC | 9.81e-23 | 4.27e-01 | 0.1122 |
| 51765 | STK26 | P15T-E | Human | Esophagus | ESCC | 5.28e-07 | 9.05e-02 | 0.1149 |
| 51765 | STK26 | P16T-E | Human | Esophagus | ESCC | 4.15e-05 | 1.07e-02 | 0.1153 |
| 51765 | STK26 | P17T-E | Human | Esophagus | ESCC | 4.01e-08 | 1.49e-01 | 0.1278 |
| 51765 | STK26 | P20T-E | Human | Esophagus | ESCC | 2.09e-10 | 1.89e-01 | 0.1124 |
| 51765 | STK26 | P21T-E | Human | Esophagus | ESCC | 2.48e-09 | 1.12e-01 | 0.1617 |
| 51765 | STK26 | P22T-E | Human | Esophagus | ESCC | 1.44e-28 | 3.65e-01 | 0.1236 |
| 51765 | STK26 | P23T-E | Human | Esophagus | ESCC | 1.07e-08 | 3.65e-01 | 0.108 |
| 51765 | STK26 | P24T-E | Human | Esophagus | ESCC | 1.74e-12 | 2.27e-01 | 0.1287 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
| GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
| GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
| GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
| GO:00703018 | Esophagus | ESCC | cellular response to hydrogen peroxide | 68/8552 | 98/18723 | 1.70e-06 | 2.03e-05 | 68 |
| GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
| GO:003647320 | Esophagus | ESCC | cell death in response to oxidative stress | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:00300339 | Esophagus | ESCC | microvillus assembly | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
| GO:190288220 | Esophagus | ESCC | regulation of response to oxidative stress | 58/8552 | 98/18723 | 4.86e-03 | 1.88e-02 | 58 |
| GO:190040720 | Esophagus | ESCC | regulation of cellular response to oxidative stress | 52/8552 | 89/18723 | 1.04e-02 | 3.56e-02 | 52 |
| GO:190320120 | Esophagus | ESCC | regulation of oxidative stress-induced cell death | 44/8552 | 74/18723 | 1.18e-02 | 3.94e-02 | 44 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STK26 | SNV | Missense_Mutation | c.1177N>T | p.Pro393Ser | p.P393S | Q9P289 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.979) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| STK26 | SNV | Missense_Mutation | novel | c.951N>C | p.Glu317Asp | p.E317D | Q9P289 | protein_coding | tolerated(0.84) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| STK26 | SNV | Missense_Mutation | c.385T>G | p.Leu129Val | p.L129V | Q9P289 | protein_coding | deleterious(0.01) | probably_damaging(0.916) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STK26 | SNV | Missense_Mutation | novel | c.1165N>A | p.Glu389Lys | p.E389K | Q9P289 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| STK26 | SNV | Missense_Mutation | novel | c.876G>C | p.Lys292Asn | p.K292N | Q9P289 | protein_coding | deleterious(0.02) | possibly_damaging(0.688) | TCGA-MU-A8JM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STK26 | SNV | Missense_Mutation | novel | c.382N>T | p.Ile128Phe | p.I128F | Q9P289 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STK26 | SNV | Missense_Mutation | c.1240N>A | p.Glu414Lys | p.E414K | Q9P289 | protein_coding | tolerated_low_confidence(0.07) | benign(0.014) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| STK26 | SNV | Missense_Mutation | c.181N>A | p.Glu61Lys | p.E61K | Q9P289 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STK26 | SNV | Missense_Mutation | novel | c.77N>C | p.Lys26Thr | p.K26T | Q9P289 | protein_coding | tolerated(0.05) | benign(0.202) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STK26 | SNV | Missense_Mutation | novel | c.775N>T | p.Pro259Ser | p.P259S | Q9P289 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |